H.R.6930 addresses the US drug supply chain’s reliance on foreign countries like China, works to mitigate drug shortages, and incentivizes the domestic manufacturing of drugs, active pharmaceutical ingredients (API), personal protective equipment (PPE), and diagnostics.
July 13, 2020
The Honorable Buddy Carter
1st Congressional District of Georgia
2432 Rayburn House Office Building
Washington, DC 20515
Cc: Senator Tim Scott (SC)
Dear Congressman Carter,
On behalf of the 2.18 million members of AMAC – Association of Mature American Citizens, including over 5500 residing in GA-01, I write to offer our support for H.R. 6930, the Manufacturing API, Drugs, and Excipients (MADE) in America Act.
The COVID-19 pandemic has certainly exposed our pharmaceutical supply chain’s reliance on foreign nations for much of the medications prescribed by American physicians. Current shortages of drugs and supplies were exacerbated once the coronavirus began to spread.
H.R.6930 addresses our drug supply chain’s dependence on foreign countries like China and works to mitigate drug shortages while incentivizing the domestic manufacturing of drugs, active pharmaceutical ingredients (API), personal protective equipment (PPE), and diagnostics. The bill designates Opportunity Zones located throughout the United States where manufacturers would receive a new tax credit to produce drugs, API, and other important supplies.
H.R. 6930 also includes provisions to lessen drug shortages by improving FDA oversight of facilities, increased diligence when working with overseas regulators and streamlining FDA standardization processes for supervising pharmaceutical manufacturing.
Thank you, Congressman Carter and Senator Scott, for working to provide incentives to increase domestic production of pharmaceuticals and critical medical supplies. Your legislation not only levels the manufacturing playing field, but also addresses national security issues by reducing America’s dependence on foreign countries for pharmaceuticals and equipment. AMAC appreciates your efforts and is pleased to offer our organization’s full support for H.R. 6930, the Manufacturing API, Drugs, and Excipients (MADE) in America Act.